![\"\"](\"http:\/\/www.sinotau.com\/wp-content\/uploads\/2023\/10\/640-2-1.jpg\")
<\/figure><\/div>\n\n\u00a0<\/p>\n
About Guangdong Sinotau Molecular Imaging Technology Co., Ltd.<\/strong> About Sinotau Pharmaceutical\u00a0Group<\/strong> Guangdong Sinotau Molecular Imaging Technology Co., Ltd.,\u00a0a subsidiary of Sinotau,\u00a0has successfully obtained the “Radiopharmaceutical Production License” A certificate, which means Guangdong Sinotau Molecular Imaging Technology Co., Ltd. has the production site qualification of radiopharmaceuticals. This is also the second qualification certificate of radiopharmaceutical production license obtained by Sinotau, which provides\u00a0GMP-compliant premises and facilities for the […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[11],"tags":[],"class_list":["post-3825","post","type-post","status-publish","format-standard","hentry","category-company-news"],"meta_box":[],"_links":{"self":[{"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/posts\/3825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/comments?post=3825"}],"version-history":[{"count":1,"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/posts\/3825\/revisions"}],"predecessor-version":[{"id":3826,"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/posts\/3825\/revisions\/3826"}],"wp:attachment":[{"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/media?parent=3825"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/categories?post=3825"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/tags?post=3825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
As the R&D and production base of Sinotau in South China, Guangdong Sinotau Molecular Imaging Technology Co., Ltd. is mainly engaged in the R&D, production,\u00a0as well as promotion and sales of innovative radiopharmaceuticals, equipped with advanced R&D\u00a0and production facilities and testing equipment in accordance with GMP requirements, which can meet the R&D and production\u00a0and\u00a0market demand\u00a0of a variety of nuclide products such as\u00a018F,\u00a068Ga,\u00a064Cu,\u00a0177Lu, etc.<\/p>\n
Sinotau Pharmaceutical\u00a0Group\u00a0officially launched the R&D of new generation radiopharmaceuticals in 2014.\u00a0Sinotau,\u00a0headquartered in Beijing,\u00a0has\u00a0modern radiopharmaceutical smart production bases in Jiangsu, Guangdong and Sichuan, and a branch office in the US,\u00a0having formed business cooperation with more than a dozen multinational pharmaceutical companies. Relying on the world’s leading R&D resources of radiopharmaceutical\u00a0precision\u00a0diogsis and therapy, Sinotau has taken the lead in laying out a number of targeted therapeutic and precision diagnostic radiopharmaceuticals in the fields of oncology, neurodegenerative diseases and cardiovascular disease, which are in or have completed clinical trials and will be launched in the coming years. Since April 2020,\u00a0Sinotau\u00a0has successfully\u00a0closed\u00a0nearly 1 billion RMB\u00a0and has\u00a0been favored by\u00a0major investment institutions, with plans to land on major capital marekts in the near future.<\/p>","protected":false},"excerpt":{"rendered":"